SNIPR-001 is under clinical development by SNIPR Biome and currently in Phase I for Escherichia coli Infections. According to GlobalData, Phase I drugs for Escherichia coli Infections does not have sufficient historical data to build an indication benchmark PTSR for Phase I. GlobalData uses proprietary data and analytics to create drugs-specific PTSR and LoA in the SNIPR-001 LoA Report. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

SNIPR-001 overview

SNIPR-001 is under development for the treatment of E. coli colonisation in the gut and hematological cancer. It is administered orally and intravenous. It is being developed based on CGV (CRISPR-Guided Vectors) technology.

SNIPR Biome overview

SNIPR Biome, a Danish biotech startup that develops CRISPR technology for the treatment of microbial diseases.

For a complete picture of SNIPR-001’s drug-specific PTSR and LoA scores, buy the report here.

This content was updated on 10 June 2024

Data Insights


The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.